TITLE

Assessing and treating radiotherapyassociated diarrhea

AUTHOR(S)
Furlow, Bryant
PUB. DATE
January 2013
SOURCE
Oncology Nurse Advisor;January/February 2013, Vol. 4 Issue 1, p41
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article examines the evaluation and treatment of diarrhea associated with radiotherapy. It discusses the findings of research suggesting that probiotics might prevent radiotherapy-associated diarrhea, particularly for patients with receiving pelvic radiotherapy. It also cites the guidelines from the Oncology Nursing Society (ONS) which indicate that selenium, sulfasalazine, pentosan polysulfate are unlikely to benefit patients with radiotherapy-associated diarrhea.
ACCESSION #
88088489

 

Related Articles

  • Adjuvant R adiotherapy. Maximilian, Rudert; Boris Michael, Holzapfel; Michael Georg, Jakubietz // Deutsches Aerzteblatt International;8/19/2011, Vol. 108 Issue 33, p6 

    In this article the author presents his views on treatment and diagnosis of soft tissue sarcomas of the limbs. They recommends magnetic resonance tomography-aided planning for the diagnosis of the small tumors. They also recommended radiotherapy for treating high-grade sarcomas. They also states...

  • Putting Evidence Into Practice. Muehlbauer, Paula M.; Thorpe, Deborah; Davis, Arlene; Drabot, Rachael; Rawlings, Barbara L.; Kiker, Elizabeth // Clinical Journal of Oncology Nursing;Jun2009, Vol. 13 Issue 3, p336 

    Diarrhea is a common side effect of chemotherapy regimens, particularly fluorouracil- and irinotecan-based therapies and abdominal and pelvic radiation regimens. Diarrhea can cause depletion of fluids and electrolytes, malnutrition, dehydration, and hospitalization, all of which can lead to...

  • Unnecessary radiation exposure from medical imaging in the rheumatology patient. Picano, Eugenio; Matucci-Cerinic, Marco // Rheumatology;Sep2011, Vol. 50 Issue 9, p1537 

    No abstract available.

  • Prevention and management of radiation-induced dermatitis, mucositis, and xerostomia. RADVANSKY, LAUREN J.; PACE, MAKALA B.; SIDDIQUI, ASIF // American Journal of Health-System Pharmacy;6/15/2013, Vol. 70 Issue 12, p1025 

    Purpose. Current strategies for preventing and managing radiation-induced dermatitis, mucositis, and xerostomia are reviewed, with an emphasis on pharmacologic interventions. Summary. Nearly two thirds of all patients with cancer receive radiation therapy during the course of treatment,...

  • Osteopontin Knockout Does Not Influence the Severity of Rectal Damage in a Preclinical Model of Radiation Proctitis in Mice. Blirando, Karl; Mintet, Elodie; Buard, Valérie; Sabourin, Jean-Christophe; Benderitter, Marc; Milliat, Fabien; François, Agnès // Digestive Diseases & Sciences;Jun2015, Vol. 60 Issue 6, p1633 

    Background: Radiation damage to the normal gut is a dose-limiting factor in the application of radiation therapy to treat abdominal and pelvic cancers. All tissue cell types react in concert to orchestrate an acute inflammatory reaction followed by a delayed chronic scarring process. Osteopontin...

  • Causes of infectious diarrhoea. van Wyk, Haley // South African Pharmaceutical Journal;2015, Vol. 82 Issue 9, p23 

    Acute-onset diarrhoea is common, and is generally caused by infection with a variety of viruses, bacteria or parasites. Acute diarrhoea may lead to life-threatening dehydration and electrolyte disturbances. When diarrhoea is not halted, there is a risk of disturbed digestion and the absorption...

  • A core outcome set for clinical trials in acute diarrhoea. Karas, Jacek; Ashkenazi, Shai; Guarino, Alfredo; Lo Vecchio, Andrea; Shamir, Raanan; Vandenplas, Yvan; Szajewska, Hania // Archives of Disease in Childhood;Apr2015, Vol. 100 Issue 4, p359 

    Objective: Core outcome sets are the baseline for what should be measured in clinical research and, thus, should serve as a guide for what should be collected and reported. The Consensus Group on Outcome Measures Made in Pediatric Enteral Nutrition Clinical Trials, established in 2012, agreed...

  • Overall survival in response to sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis: propensity score analysis. Nakazawa, Takahide; Hidaka, Hisashi; Shibuya, Akitaka; Okuwaki, Yusuke; Tanaka, Yoshiaki; Takada, Juichi; Minamino, Tsutomu; Watanabe, Masaaki; Kokubu, Shigehiro; Koizumi, Wasaburo // BMC Gastroenterology;2014, Vol. 14 Issue 1, p1 

    Background This study investigated the survival benefits of sorafenib vs. radiotherapy (RT) in patients with unresectable hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT) in the main trunk or the first branch. Methods Ninety-seven patients were retrospectively reviewed....

  • Mayo Clinic Develops New Way to Rate Severity of Colitis, a Common Cause of Diarrhea.  // Biomedical Market Newsletter;11/7/2011, Vol. 21, p9 

    The article reports on the development of the Microscopic Colitis Disease Activity Index which evaluates common cause of chronic diarrhea by Mayo Clinic researchers in the U.S. The index released during the American College of Gastroenterology 2011 Annual Scientific Meeting, provides a...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics